NC
FLXN

Nexthera Capital’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Nexthera Capital’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-466,500
Closed -$11.7M – 57
2017
Q4 		$11.7M Buy
+466,500
New +$11.4M 2.15% 14

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Nexthera Capital's FLXN Position: Q4 2017 in Review

Nexthera Capital sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2017, closing a stake of 271,136 shares — an estimated $6.64M sold.

Nexthera Capital first reported a position in FLXN in Q2 2017 and held it in 2 quarters. The position peaked at $6.56M in Q3 2017. 138 funds tracked by Wall St. Rank hold FLXN as of Q4 2017.

  • Nexthera Capital reported no remaining Flexion Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nexthera Capital sold 271,136 Flexion Therapeutics, Inc. shares in Q4 2017, an estimated $6.64M.
  • Nexthera Capital first reported a position in Flexion Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Nexthera Capital's Flexion Therapeutics, Inc. position peaked at $6.56M in Q3 2017.
  • 138 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2017.

Based on Nexthera Capital's 13F filing for Q4 2017, filed 14 Feb 2018.